Anixa Biosciences Inc ANIX Cash Flow

Anixa biosciences inc (ANIX)

CashFlow / TTM

Jan'20	Oct'19	Jul'19	Apr'19	Jan'19	Oct'18	Jul'18	Apr'18	Jan'18	Oct'17	Jul'17	Apr'17	Jan'17	Oct'16	Jul'16	Apr'16	Jan'16	Oct'15	Jul'15	Apr'15	Jan'15	Oct'14	Jul'14	Apr'14	Jan'14	Oct'13	Jul'13	Apr'13	Jan'13	Oct'12	Jul'12	Apr'12	Jan'12	Oct'11	Jul'11	Apr'11	Jan'11
Accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	95	67	-365	-868	-868	-816	185	-27	97	117	145	641	614	445	460	174	239	146	28	10	0	0	0
Royalties and contingent legal fees payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-213	-275	-49	-57	-347	123	-239	219	352	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-940	0	0	0	-	-	-	-
Cash flows from operating activities:
Net loss
-9,468	-11,818	-15,099	-18,526	-17,344	-14,243	-10,637	-6,838	-5,285	-5,008	-4,270	-3,580	-5,012	-5,016	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,379	-3,240	-1,226	-2,239	-9,606	-9,379	-12,372	-11,599	-10,080	-9,013	-7,061	-5,461	-4,252	-5,183	-6,328	-6,738	-7,378	0	0	0
Stock option compensation to employees and directors
3,305	3,560	4,927	7,269	6,722	5,717	3,885	1,240	1,174	1,219	1,236	995	1,020	873	908	1,448	2,297	2,676	3,141	2,830	2,920	3,149	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Stock options and warrants issued to consultants
209	198	203	284	311	318	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted stock award compensation to employee pursuant to stock incentive plan
-	1,954	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of interest on patent acquisition obligations to interest expense
-	-	-	-	-	-	-	-	-	228	-364	-497	-537	-519	-501	-484	-684	-451	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common stock issued to consultants
-	-	-	-	-	-	-	-	-	-	-	37	42	31	27	51	48	46	90	55	60	84	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation of property and equipment
-	-	-	-	-	-	-	29	37	43	40	40	39	33	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Depreciation of property and equipment
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Amortization of operating lease right-to-use asset, net of lease payments
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock option compensation to employees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,693	0	0	0	-	-	-	-	-	-	-	-
Stock option compensation to consultants
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common stock issued to consultants
-	-	-	-	-	15	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock option compensation to consultants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Common stock issued to consultants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Amortization of patents
-	418	500	539	495	325	325	325	325	325	325	325	325	325	325	325	325	325	325	325	325	314	233	151	70	0	0	0	0	-	-	-	-	-	-	-	-
Impairment in carrying amount of patent asset
-	418	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of noncontrolling interest in Certainty Therapeutics, Inc. expensed as a license fee
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortized interest on patent acquisition obligations to interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of convertible debenture discount charge to interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	634	673	636	1,203	991	0	0	0	-	-	-	-	-	-	-	-
Accrued interest on secured debenture
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	61	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Change in value of derivative liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-592	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of noncontrolling interest in Certainty Therapeutics, Inc. expensed as a license fee
-	-	-	-	-	64	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common stock issued
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Common stock issued to acquire patent license
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in operating assets and liabilities:
Gain on sale of Digital Info Security Co., Inc. common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-30	0	0	0
Other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-58	-55	-46	-38	26	27	26	-9	-21	-28	-25	7	0	0	0	-	-	-	-
Accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	225	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Receivables
-112	-271	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
-76	9	-160	-84	0	48	-23	191	209	12	304	25	12	35	-137	-3	-10	65	93	-91	-74	-100	26	55	47	78	0	0	0	-	-	-	-	45	0	0	0
Accounts payable
-245	3	148	265	196	101	-46	3	-123	107	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses
-9	212	165	-10	44	273	269	676	486	313	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-5,326	-4,741	-4,425	-4,955	-4,262	-4,273	-3,991	-4,072	-4,406	-3,796	-3,740	-3,303	-3,579	-3,381	-3,500	-3,394	-3,822	1,363	1,803	2,174	3,445	-2,379	-2,561	-3,063	-3,468	-3,186	-3,604	-3,393	-3,373	-3,140	-2,890	-930	-763	-716	0	0	0
Cash flows from investing activities:
Disbursements to acquire short-term investments in certificates of deposit
0	-	-	-	-	4,250	5,250	4,501	6,751	5,501	4,251	2,600	1,650	1,900	2,250	2,050	2,500	2,900	4,050	4,900	3,150	5,200	0	0	0	-	-	-	-	1,200	0	0	0	-	-	-	-
Proceeds from maturities of short-term investments in certificates of deposit
4,600	3,500	3,250	2,500	3,900	5,750	6,751	5,501	4,701	2,751	1,900	2,500	3,200	3,550	2,750	2,300	3,000	3,000	4,200	4,550	2,950	2,700	1,400	900	500	750	949	1,748	2,998	2,948	0	0	0	-	-	-	-
Proceeds from sale of Digital Info Security Co. Inc. common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	118	0	0	0
Purchase of property and equipment
0	-	-	-	-	38	45	27	18	30	18	19	54	146	144	141	106	54	0	0	0	-	-	-	-	-	-	-	-	-	1	2	3	9	0	0	0
Other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-
Net cash (used in) provided by investing activities
-1,311	-525	467	-1,702	864	1,461	1,500	1,017	-2,023	-2,735	-2,369	-119	1,495	1,503	355	108	393	45	92	-410	-261	-2,506	-2,553	-2,052	-2,449	499	949	1,550	2,047	1,747	2,047	-201	-1,955	-2,138	0	0	0
Cash flows from financing activities:
Proceeds from issuance of convertible debentures
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,500	3,500	3,500	3,500	1,765	0	0	0	-	-	-	-	-	-	-	-
Net proceeds from sale of common stock in at-the-market offering
5,125	5,527	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Redemption of convertible preferred stock
-	-	-	-	-	-	-	-	-	500	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
127	122	0	0	0	-	-	-	-	7	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	208	393	915	953	1,284	0	0	0
Net cash provided by financing activities
5,306	5,702	0	0	0	-	-	-	-	7,382	0	0	0	-	-	-	-	-	-	-	-	7,349	7,784	4,460	4,980	3,245	3,535	2,986	2,576	958	393	915	2,203	2,534	0	0	0
Net (decrease) increase in cash and cash equivalents
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash and cash equivalents
-	-	-	-	-	-	-	1,295	1,446	851	-215	264	-2,580	-1,880	-3,111	-3,467	-3,828	1,007	1,509	5,462	7,033	2,463	2,669	-656	-937	558	880	1,143	1,250	-434	-449	-216	-515	-320	0	0	0
Supplemental disclosure of non-cash investing and financing activities:
Operating lease right-to-use asset
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease liability
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments to suppliers, employees and consultants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,164	1,486	-3,164	-4,563	-3,280	0	0	0
Cash received from sales of products and services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5	32	119	130	0	0	0
Redemption of Series A convertible preferred stock into secured debenture (Note 5)
-	-	-	-	-	-	-	-	-	3,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair value of debenture embedded conversion feature, at issuance
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,570	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Relative fair value of convertible debenture warrant, at issuance
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	513	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-5,326	-4,741	-4,425	-4,955	-4,262	-4,273	-3,991	-4,072	-4,406	-3,796	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-3,604	-3,393	-3,373	-3,140	-2,890	-930	-763	-716	0	0	0